ID   ALL-VG TKI-resistant
AC   CVCL_C1MF
DR   cancercelllines; CVCL_C1MF
DR   Wikidata; Q114310623
RX   PubMed=28650474;
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1785; CDKN1B; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:3495; ETV6; Name(s)=ETV6-ABL1 (PubMed=28650474).
CC   Sequence variation: Mutation; HGNC; HGNC:4396; GNB1; Simple; p.Lys89Met (c.266A>T); ClinVar=VCV001360749; Zygosity=Heterozygous; Note=Involved in imatinib resistance (PubMed=28650474).
CC   Omics: Deep exome analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C1ME ! ALL-VG
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 6
//
RX   PubMed=28650474; DOI=10.1038/onc.2017.210; PMCID=PMC5666322;
RA   Zimmermannova O., Doktorova E., Stuchly J., Kanderova V.,
RA   Kuzilkova D., Strnad H., Starkova J., Alberich-Jorda M.,
RA   Falkenburg J.H.F., Trka J., Petrak J., Zuna J., Zaliova M.;
RT   "An activating mutation of GNB1 is associated with resistance to
RT   tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.";
RL   Oncogene 36:5985-5994(2017).
//